Decreasing total exposure to opioids in the operative and postoperative periods has become a focus of recent efforts to control the opioid crisis. Regional anesthesia, specifically, thoracic paravertebral blocks, have been shown in mastectomy to decrease pain and aid in early discharge; however, the use of this technique has not been explored in outpatient procedures such as breast reduction mammoplasty (BRM). Here we seek to determine the effects of thoracic paravertebral blocks on pain and opioid consumption in patients undergoing BRM.
RESULTS:
One hundred and six patients were included for analysis (block n=58 (54.7%) , no block n=48 (45.3%)). Age, BMI, reduction specimen weight, and co-morbidities did not differ between groups. Intraoperatively, opioid consumption was significantly lower in patients with paravertebral blocks (block 19.6 ± 11.7 MME, no block 24 ± 10.4 MME; p<0.001). Furthermore, length of surgery was significantly longer in patients who did not receive a block (block 175.1 ± 24.0 minutes, no block 185.8 ± 25.2 minutes; p = 0.027). In the immediate postoperative period, there was no difference in opioid consumption between groups (block 5.9 ± 4.4 MME, no block 5.2 ± 4.2 MME; p=0.381). However, a significantly higher proportion of patients without blocks received any dose of non-opioid analgesic for pain management (block n= 16 (27.6%), no block n=24 (50.0%); p=0.018). Patient-reported pain scores did not differ between groups in the immediate postoperative period (block 5.0 ± 3.6, no block 5.8 ± 2.0; p=0.264). Time to discharge of patients from the PACU was significantly lower in patients with paravertebral blocks (block 253.6 ± 94.5 min, no block 380 ± 209 min; p<0.001). The cost of the paravertebral block ($215.64) was less than the cost of increased time in the PACU ($556.16).
CONCLUSION:
Patients undergoing preoperative paravertebral block have decreased intraoperative opioid use as compared to those undergoing general anesthesia alone. In the postoperative period, patients having no block received more non-opioid pain medications but had similar postoperative pain and use of opioids. Of interest, both length of surgery and time to discharge from recovery are shorter in patients who underwent block. Additionally, the use of the paravertebral block was economically beneficial due to cost savings from decreased time in the PACU. Therefore, use of preoperative paravertebral blocks in concert with postoperative non-opioid analgesia is suggested and necessary to decrease overall opioid exposure, to reduce both operative and recovery time, and decrease healthcare costs. 
PURPOSE:
The rise in alloplastic breast reconstruction has revealed a rare but serious associated malignancy, breast-implant associated anaplastic large cell lymphoma (BIA-ALCL). The first case of BIA-ALCL was diagnosed in 1997, but due to the novelty and low prevalence of this condition, many unknown characteristics remain. The aim of this study was to systematically review the literature on BIA-ALCL and to reveal certain patterns in terms of patient demographics, presenting symptoms, geographical distribution, associated biological markers, and treatment options.
METHODS:
PubMed, Google scholar and EBSCOhost were searched to find all publications pertaining to BIA-ALCL. The terms "Breast Implant" and "Anaplastic Large Cell Lymphoma" were used as keywords and 'exploded' to include articles indexed with these headings as well as those indexed with any related terms. Inclusion criteria consisted of case reports or case series that describe BIA-ALCL. Articles published in English or French, commentaries or discussions, and studies on systemic ALCL were excluded. The data extracted included patient age, time of onset, diagnosis, pathophysiology, implant type, implant manufacturer, and treatment options.
RESULTS:
Out of the 79 BIA-ALCL cases reported in the literature, 23 cases were saline filled implants and 47 were silicone filled. In the remaining cases, the type was unidentified. The mean age at diagnosis was 51.35 ± 12.47 and 52.15 ± 12.28 for patients with saline and silicone implants respectively (p>0.05). The time of onset after surgery was 10.83 ± 6.72 years and 12.04 ± 5.04 year for saline and silicone filled implant, respectively (p>0.05). The most common indication for surgery for both saline and silicone implant was cosmetic (44.30%) followed by oncotic breast reconstruction (39.24%). The most common initial presentation was seroma (26.5%) followed by swelling (24.1%), breast pain (22.7%) and palpated mass (21.5%). The most common surface type associated with BIA-ALCL was textured implants. Furthermore, 61 cases reported an Anaplastic Lymphoma Kinase Negative (ALK-) enzyme while 55 cases reported a CD30+ antigen. The main treatment options for ALCL were chemotherapy in conjunction with radiation therapy (25.31%), capsulotomy (15.18%) or chemotherapy alone (8%) ( Table  1) . Although only 79 cases were included in this review, there are many more cases that aren't scientifically published. Many cases are briefly reported by government bodies and plastic surgery associations without providing sufficient information to be useful to analyze in this review. For example, the department of health in Australia reported 72 cases of BIA-ALCL without providing specific details about them. While these cases aren't analyzed in this abstract they will be included in the presentation for a more accurate depiction of prevalence rates.
CONCLUSION:
BIA-ALCL is a relatively new and rare condition that is not fully understood. This study reviews all the published BIA-ALCL cases and describes different characteristics associated with this condition. While further understanding of BIA-ALCL continues to be pursued, this review will aid in disseminating more information about this medical entity. Cleft palate repair has rare, but potentially life-threatening risks. Understanding the risk factors for adverse events following cleft palate repair can guide surgeons in risk stratification and parental counseling. The present study seeks to characterize independent predictors of 30-day adverse events after primary cleft palate repair.
METHODS:
Using data from the National Surgical Quality Improvement Program Pediatric (NSQIP-P) database from 2012 to 2016, patients who underwent primary cleft palate repair were evaluated. All patients in the database were followed by specially-trained nurses for 30 postoperative days, regardless of discharge status. Patients experiencing any adverse event, reoperation, readmission, or wound dehiscence (palatal fistula) were identified. For each adverse event, patient demographics, comorbidities, and surgical variables were compared between patients who did and did not experience the adverse event. Separate multivariate logistic regression analyses were performed for each of the adverse events to identify independent predictors. Each regression controlled for demographics, as well as surgical variables and comorbidities that differed significantly between patients who experienced adverse events and the remaining cohort. RESULTS: 4,989 patients who underwent primary cleft palate repair with complete data were identified. Patients had a mean age of 1.0 ± 0.3 years, and 53.5% were male. A total of 6.4% (320 patients) experienced any adverse event with 154 patients (3.1%) experiencing wound dehiscence. Thirty-day readmission and reoperation rates were 2.7% and 0.9%, respectively. On multivariate analysis, perioperative blood transfusion (adjusted odds ratio [aOR] 30.4, 95% confidence interval [CI] 7.4-124.6) and bronchopulmonary dysplasia/chronic lung disease (aOR 2.1, 95% CI 1.1-4.0) were significantly associated with any adverse
